Multiple Sclerosis
Neuro solutions.
Pioneering AI solutions driving breakthroughs in Multiple Sclerosis research and clinical practice.
About Multiple Sclerosis.
Multiple sclerosis (MS) is an unpredictable autoimmune disease affecting the central nervous system, impacting 2.8 million people worldwide. It is characterized by relapsing episodes of neurologic impairment followed by remissions. Symptoms vary per patient, making personalized medicine crucial for treatment planning. Diagnosis relies on clinical assessment and MRI, guided by the McDonald criteria, to ensure sensitivity and specificity. MRI simplifies diagnosis and decision-making for initiating disease-modifying therapy (DMT), becoming the gold standard and a fundamental part of clinical routine.
How AI empowers MRI clinical workflows.
The current breakthrough in the field will soon redefine disease management, raising new scientific challenges for radiologists and neurologists. Recent clinical trial outcomes indicate that, for the first time, anti-amyloid treatment could slow cognitive decline. This breakthrough changes the paradigm of Alzheimer’s treatment and offers hope to patients and families. However, this transformation presents scientific and clinical challenges, requiring implementing a complex treatment plan, particularly in brain imaging monitoring. TheraPanacea leverages state-of-the-art technology to unlock AI-powered solutions that enhance the workflow of R&D teams and clinicians.